Thermo Fisher Scientific has announced the launch of the Cellomics Toxinsight Solution at the World Pharmaceutical Congress on 9-11 June in Philadelphia.
The Thermo Scientific Cellomics Toxinsight Solution offers a combination of imaging hardware and analysis software, and couples pre-validated panels of toxicity assessment targets, to provide a robust risk-assessment tool for in-vitro toxicity testing.
Traditional methods of assessing toxicity in vitro measure single targets and have a record of low predictive power.
Recently published research has shown that cellular imaging, which combines multiple toxicity targets in single cells, provides better indicators of compound toxicity.
Such rich profiles of cellular toxicity have the potential to revolutionise the way toxicity testing is performed, from reducing late-stage drug failures due to adverse toxicity (hence lowering overall drug development costs), to better understanding of the effect of environmental toxins, as well as ensuring the products we use are safe.
Harnessing the power of cell imaging to make multiple toxicity assessments on a cell by cell basis, the Toxinsight IVT Platform unites automated instrumentation, software, and reagent 'cartridges' within a simple, intuitive workflow, offering improved sensitivity and specificity.
